AI-generated summary
The authors studied cultured immortalized macrophages and streptozotocin-induced diabetic mice to test whether photobiomodulation therapy at 980 nm could counter diabetes-related macrophage dysfunction and periodontal tissue damage. They report that the therapy improved macrophage phagocytosis, migration and anti-inflammatory phenotype, and that combining it with insulin produced better periodontal tissue restoration than either treatment alone. The authors suggest the MEK/ERK/FOXO1 pathway may be involved.
- Who or what was studied
- Immortalized bone marrow-derived macrophages and streptozotocin-induced diabetic mice
- Wavelengths
- 980 nm
- Limits stated in the abstract
- The study used cell cultures and diabetic mice, so findings may not directly apply to human periodontitis, and the abstract does not report sample sizes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 980 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Adenosine triphosphate, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.